We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A regional United Nations meeting recently called for new funding to ensure immunization at more than 95 percent in Latin America and the Caribbean and to meet the target of eliminating rubella and congenital rubella syndrome by 2010.
Swiss drugmaker Roche has announced that its antiviral drug Tamiflu (oseltamivir) is now available for the 2006-2007 influenza season for the treatment and prevention of influenza.
Rexahn, a clinical stage biopharmaceutical company, announced that a European patent (EP 1206261) has been granted for the treatment of behavioural diseases with its leading CNS drug candidate, RX-10100.
AMDL, Inc., developer and marketer of tests for the early detection of cancer and other serious diseases, announced that the acquisition of Jade Pharmaceutical Inc. and its two wholly owned China-based subsidiaries for an aggregate of 2,743,000 post-reverse split (13,715,000 pre-reverse split) shares of AMDL Common Stock.
Global pharma majors such as Novartis, Roche, Serono and over 500 small and medium companies in life sciences, pharmaceutical industry have realised the benefits Switzerland offers.
Gilead Sciences, Inc. and Myogen, Inc. announced today that the companies have signed a definitive agreement under which Gilead plans to acquire Myogen.
Ethiopia's government has launched a major initiative against malaria, the leading cause of death in the country, at the start of the annual transmission season. Malaria infects 9 million Ethiopians each year and can kill more than 100,000, mostly young children, within just a few months during an epidemic.